Heyholder
‹ Activism Filings

GC Biopharma Corp. Q3 operating profit KRW 49.2 billion on revenue of KRW 522.1 billion (consolidated)

GC Biopharma Corp.· Periodic Report

AI summary · Not investment advice

In Q3, the company sold KRW 522.1 billion worth and earned KRW 49.2 billion from its main business, up 68.5% from a year earlier and up 2746.1% from the previous quarter.

Operating profit · 3 months

KRW 49.2 billion

Key facts

Revenue (3 months)
KRW 522.1 billion
Net income (3 months)
KRW 208.5 billion
Period
Q3 (cumulative Jan 1, 2026 to Sep 30, 2026)
Revenue (prior-year 3 months)
KRW 609.5 billion
Revenue (year to date)
KRW 1.4 trillion
Operating profit (prior-year 3 months)
KRW 29.2 billion
Operating profit (year to date)
KRW 62.7 billion
Net income (prior-year 3 months)
KRW 18.1 billion
Net income (year to date)
KRW 229.7 billion

Commentary

AI commentary · Not investment advice

What happened

GC Biopharma (Green Cross) reported its consolidated results for the third quarter of 2026. Sales for the 3 months were KRW 522.1 billion. That is 14.3% lower than the same 3 months a year earlier and 24.0% higher than the previous quarter.

In the company's terms

Operating profit (profit from the core business) for the 3 months was KRW 49.2 billion. That is 68.5% higher than a year earlier and 2746.1% higher than the previous quarter.

What changes for shareholders

Net income (the final profit after taxes and all other costs) for the 3 months was KRW 208.5 billion. That is 1048.9% higher than a year earlier and 19754.9% higher than the previous quarter.

For the year so far, sales are KRW 1,378.9 billion. Operating profit is KRW 62.7 billion. Net income is KRW 229.7 billion.

Comments

No comments yet

Comments from shareholders will appear here.